Drug Database
Back to search

Ireland· IE-PA-EU/1/17/1209/011-020

Reagila 3 mg hard capsules

A cariprazine product containing cariprazine hydrochloride, registered in Ireland by Gedeon Richter Plc. The same ATC class is registered in 14 of our 19 countries.

ATC N05AX15

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedReagila 3 mg hard capsulesATCN05AX15REGISTER NO.IE-PA-EU/1/17/1209/01…PACKS LISTED1CHECKEDSeptember 28, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about cariprazine hydrochlorideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Cariprazine is registered in 14 of 19 countries.

Countries holding a registration under ATC N05AX15 (cariprazine), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 9 of them publish a price we can compare per daily dose
Search cariprazine products by name

Cariprazine · ATC N05AX15

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of cariprazine costs, country by country.

Normalised to the WHO defined daily dose (3 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Cariprazine · price per daily dose (3 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$5.85
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

HPRA (Ireland)
Active substance
Cariprazine hydrochloride
Manufacturer
Gedeon Richter Plc
Country
Ireland (IE)
ATC code
N05AX15
ATC class
Cariprazine
Defined daily dose
3 mg, O
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    EU/1/17/1209/011-020

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

219 interactions on record for cariprazine.

Graded by severity as the source publishes them — 18 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check cariprazine against other medicinesHow interaction checks work

Cariprazine · interactions on record

219 records

  • 18 severe
  • 201 moderate

Most severe, free to view

  • MetoclopramideA03FA01severe
  • KetoconazoleH02CA03severe
  • ClarithromycinJ01FA09severe
  • KetoconazoleJ02AB02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Cariprazine in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cariprazine products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Reagila
  • Liechtenstein · Reagila
  • Norway · Reagila

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/5f62c731-6799-4f5a-8a83-e03760b7edcd
GET /v1/drugs/5f62c731-6799-4f5a-8a83-e03760b7edcd?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "routes": [
    "Oral use"
  ],
  "source": "hpra",
  "atc_all": [
    "N05AX",
    "N05AX15"
  ],
  "strength": null,
  "pa_number": "EU/1/17/1209/011-020",
  "substances": [
    "Cariprazine hydrochloride"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Unknown",
  "authorised_at": "13/07/2017",
  "dispensing_status": "Product subject to prescription which may be renewed (B)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}
API referenceMCP serverPlans

See everything about cariprazine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console